Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
J Mol Microbiol Biotechnol ; 27(3): 133-146, 2017.
Article in English | MEDLINE | ID: mdl-28456803

ABSTRACT

BACKGROUND: Arginine deiminase (ArcA) has been speculated to facilitate the intracellular survival of Streptococcus suis under acidic conditions. However, the physical and biological properties and function of SS2-ArcA have not yet been elucidated. METHODS: Recombinant SS2-ArcA (rSS2-ArcA) was expressed and purified using Ni-NTA affinity chromatography. Under various pH and temperature conditions, the enzymatic properties of purified rSS2-ArcA and crude native SS2-ArcA were determined. RESULTS: The SS2-arcA-deduced amino acid sequence contained a conserved catalytic triad (Cys399-His273-Glu218). The optimum temperature and pH of 47-kDa rSS2-ArcA and crude native SS2-ArcA were 42°C and pH 7.2. The rSS2-ArcA and crude native SS2-ArcA were stable for 3 h at 4 and 25°C, respectively. The pH stability and dependency tests suggested that rSS2-ArcA and crude native SS2-ArcA were functionally active in acidic conditions. The L-arginine substrate binding affinity (Km) values of rSS2-ArcA (specific activity 16.00 U/mg) and crude native SS2-ArcA (specific activity 0.23 U/mg) were 0.058 and 0.157 mM, respectively. rSS2-ArcA exhibited a weak binding affinity with the common ArcA inhibitors L-canavanine and L-NIO. Furthermore, the partial inactivation of SS2-ArcA significantly impaired the viability and growth of SS2 at pH 4.0, 6.0, and 7.5. CONCLUSIONS: This study profoundly demonstrated the involvement of ArcA enzymatic activity in S. suis survival under acidic conditions.


Subject(s)
Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Hydrolases/chemistry , Hydrolases/genetics , Serogroup , Streptococcus suis/enzymology , Streptococcus suis/genetics , Amino Acid Sequence , Arginine/metabolism , Bacterial Proteins/drug effects , Bacterial Proteins/metabolism , Base Sequence , Canavanine/antagonists & inhibitors , Cloning, Molecular , Enzyme Assays , Escherichia coli/genetics , Gene Expression Regulation, Bacterial , Genes, Bacterial , Hydrogen-Ion Concentration , Hydrolases/drug effects , Hydrolases/metabolism , Kinetics , Ornithine/analogs & derivatives , Ornithine/antagonists & inhibitors , Protein Stability , Recombinant Proteins/biosynthesis , Recombinant Proteins/isolation & purification , Sequence Alignment , Streptococcus suis/metabolism , Temperature
2.
Food Res Int ; 92: 56-63, 2017 02.
Article in English | MEDLINE | ID: mdl-28290298

ABSTRACT

Advanced Glycation End-products (AGEs) have been associated to diabetes, neurodegenerative and cardiovascular diseases. Mitigating the formation of AGEs is a strategy to avoid detrimental physiopathological effects of age-related chronic diseases. An olive leaf extract (OLE), obtained under acidic conditions, and two fractions, obtained by solid-phase extraction, were characterized by LC-MS/MS. Antiglycative capacity of OLE and fractions were investigated in different in vitro models. The OLE significantly inhibited the formation of Amadori products at the early stage as well as the formation of fluorescent AGEs at the advanced stage of the glycation. Carboxymethyllysine was significantly inhibited by the OLE but it showed weaker activity against argpyrimidine and carboxyethyllysine. The antiglycative activity of each OLE fraction independently did not explain the activity reached in the whole extract, being necessary the compounds present in both fractions. OLE and its fractions were highly effective for trapping reactive dicarbonyl compounds (glyoxal, methylglyoxal, 3-deoxyglucosone and 3-deoxygalactosone). Different adducts resulting from the conjugation of methylglyoxal and hydroxytyrosol in OLE were identified. Results pointed out that OLE exert a broad-spectrum in vitro antiglycative activity.


Subject(s)
Olea/chemistry , Plant Extracts/pharmacology , Plant Leaves/chemistry , Chromatography, Liquid , Deoxyglucose/analogs & derivatives , Deoxyglucose/metabolism , Fructosamine/antagonists & inhibitors , Fructosamine/metabolism , Galactose/analogs & derivatives , Galactose/metabolism , Glycation End Products, Advanced/antagonists & inhibitors , Glycation End Products, Advanced/metabolism , Glycosylation , Glyoxal/metabolism , Lysine/analogs & derivatives , Lysine/antagonists & inhibitors , Lysine/metabolism , Ornithine/analogs & derivatives , Ornithine/antagonists & inhibitors , Ornithine/metabolism , Phenols/pharmacology , Phenylethyl Alcohol/analogs & derivatives , Phenylethyl Alcohol/metabolism , Pyrimidines/antagonists & inhibitors , Pyrimidines/metabolism , Pyruvaldehyde/metabolism , Tandem Mass Spectrometry
3.
J Biol Chem ; 274(10): 6754-62, 1999 Mar 05.
Article in English | MEDLINE | ID: mdl-10037775

ABSTRACT

Delta1-Pyrroline-5-carboxylate synthase (P5CS; EC not assigned), a mitochondrial inner membrane, ATP- and NADPH-dependent, bifunctional enzyme, catalyzes the reduction of glutamate to Delta1-pyrroline-5-carboxylate, a critical step in the de novo biosynthesis of proline and ornithine. We utilized published plant P5CS sequence to search the expressed sequence tag data base and cloned two full-length human P5CS cDNAs differing in length by 6 base pairs (bp) in the open reading frame. The short cDNA has a 2379-bp open reading frame encoding a protein of 793 residues; the long cDNA, generated by "exon sliding," a form of alternative splicing, contains an additional 6-bp insert following bp +711 of the short form resulting in inclusion of two additional amino acids in the region predicted to be the gamma-glutamyl kinase active site of P5CS. The long form predominates in all tissues examined except gut. We also isolated the corresponding long and short murine P5CS transcripts. To confirm the identity of the putative P5CS cDNAs, we expressed both human forms in gamma-glutamyl kinase- and gamma-glutamyl phosphate reductase-deficient strains of Saccharomyces cerevisiae and showed that they conferred the proline prototrophy. Additionally, we found expression of the murine putative P5CS cDNAs conferred proline prototrophy to P5CS-deficient Chinese hamster ovary cells (CHO-K1). We utilized stable CHO-K1 cell transformants to compare the biochemical characteristics of the long and short murine P5CS isoforms. We found that both confer P5CS activity and that the short isoform is inhibited by L-ornithine with a Ki of approximately 0.25 mM. Surprisingly, the long isoform is insensitive to ornithine inhibition. Thus, the two amino acid insert in the long isoform abolishes feedback inhibition of P5CS activity by L-ornithine.


Subject(s)
Gene Expression Regulation, Enzymologic , Oxidoreductases Acting on CH-NH Group Donors/genetics , 1-Pyrroline-5-Carboxylate Dehydrogenase , Alternative Splicing , Amino Acid Sequence , Animals , CHO Cells , Cricetinae , DNA, Complementary/genetics , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Mice , Molecular Sequence Data , Organ Specificity , Ornithine/antagonists & inhibitors , Ornithine/metabolism , Oxidoreductases Acting on CH-NH Group Donors/metabolism , Sequence Alignment , Substrate Specificity
4.
Am J Physiol ; 271(5 Pt 2): R1149-55, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8945947

ABSTRACT

This study was designed to test the hypothesis that endogenous arginine synthesis plays an important role in maintaining arginine homeostasis in neonatal pigs. Gabaculine was used as a suicide inhibitor of ornithine aminotransferase to decrease the intestinal conversion of glutamine-derived pyrroline-5-carboxylate (P-5-C) into ornithine, the precursor of both citrulline and arginine. Four-day-old suckling pigs received oral administration of 0.0 or 0.83 mg gabaculine/kg body wt every 4 h during a 12-h period from 6 A.M. to 6 P.M. Blood was collected from piglet's jugular vein at 6 A.M. and 6 P.M. after a 2-h isolation from sows. Gabaculine treatment decreased plasma concentrations of ornithine, citrulline, and arginine by 59, 52, and 76%, respectively, and increased those of glutamine and proline by 74 and 220%, respectively. The gabaculine treatment also increased plasma concentrations of leucine, taurine, and ammonia by 29, 42, and 20%, respectively. There were no differences in intramuscular concentrations of amino acids between control and gabaculine-treated pigs. Because P-5-C synthase (the enzyme required for synthesis of P-5-C from glutamate) was almost exclusively located in enterocytes of 4-day-old pigs, our data suggest that the intestinal production of citrulline plays an important role in endogenous synthesis of arginine and its homeostasis in neonatal pigs.


Subject(s)
Animals, Newborn/metabolism , Arginine/metabolism , Homeostasis , Administration, Oral , Amino Acids/blood , Amino Acids/metabolism , Animals , Arginine/antagonists & inhibitors , Citrulline/antagonists & inhibitors , Cyclohexanecarboxylic Acids/pharmacology , Glutamine/metabolism , Intestinal Mucosa/metabolism , Intestines/cytology , Muscle, Skeletal/metabolism , Ornithine/antagonists & inhibitors , Ornithine-Oxo-Acid Transaminase/metabolism , Pyrroles/metabolism , Swine
5.
Eur J Pharmacol ; 296(1): 23-31, 1996 Jan 18.
Article in English | MEDLINE | ID: mdl-8720473

ABSTRACT

L-Arginine produces central antinociception by acting as a precursor of kyotorphin (L-tyrosyl-L-arginine), a [Met5]enkephalin releaser. This study investigated the antinociceptive activity of L-ornithine, a metabolite of L-arginine. L-Ornithine given s.c. at 300-1000 mg/kg suppressed carrageenin-induced hyperalgesia in rats in a naloxone-reversible manner. L-Ornithine and L-arginine, when given i.c.v. at 10-100 mu g/mouse, elicited antinociception even in intact mice, the effects being abolished by naloxone or naltrindole, and potentiated by bestatin, an inhibitor of aminopeptidase and kyotorphinase. The antinociception induced by i.c.v. L-ornithine was also inhibited by i.c.v. L-leucyl-L-arginine, a kyotorphin receptor antagonist, but was resistant to intracisternal anti-kyotorphin serum. L-Tyrosyl-L-ornithine, a synthetic dipeptide, (1-10 mu g/mouse, i.c.v.), exerted kyotorphin-like antinociception in mice. These findings suggest that L-ornithine produces L-arginine-like antinociception via kyotorphin receptors. However, this effect does not appear to be mediated by kyotorphin itself, but most likely by L-tyrosyl-L-ornithine, a putative dipeptide.


Subject(s)
Analgesia , Dipeptides/pharmacology , Ornithine/pharmacology , Animals , Arginine/antagonists & inhibitors , Carrageenan , Citrulline/pharmacology , Dose-Response Relationship, Drug , Excipients , Hyperalgesia/chemically induced , Hyperalgesia/prevention & control , Injections, Intraventricular , Leucine/analogs & derivatives , Leucine/pharmacology , Male , Mice , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Ornithine/administration & dosage , Ornithine/antagonists & inhibitors , Pain Measurement/drug effects , Protease Inhibitors/pharmacology , Rats
6.
Metab Brain Dis ; 8(3): 151-79, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8272027

ABSTRACT

The vertebrate brain has the machinery to transport arginine and ornithine, and to form within nerve endings from these amino acids glutamate and GABA, the major excitatory and inhibitory neurotransmitters. Ornithine aminotransferase is a key enzyme of the Arg-->Orn-->Glu-->GABA pathway; the physiological significance of this pathway is still unclear. With 5-fluoromethylornithine, a selective inactivator of ornithine aminotransferase, a tool is in our hands that allows us to study biochemical and behavioral consequences of elevated tissue ornithine concentrations. Increase of the rate of hepatic urea formation, and of ornithine decarboxylation are the most important changes in vertebrates following inactivation of ornithine aminotransferase. Administration of 5-fluoromethylornithine prevented the accumulation of lethal concentrations of ammonia in brain, and ameliorated pathological consequences of thioacetamide intoxication. Inhibition of ornithine catabolism has, therefore, potentials in the therapy of those hyperammonemic states which are characterized by a conditional deficiency of ornithine. The enhancement of polyamine formation due to elevated ornithine concentrations may allow us to favorably affect tissue regeneration following injury.


Subject(s)
Brain Diseases/drug therapy , Brain/physiology , Ornithine/physiology , Ammonia/blood , Animals , Brain Diseases/blood , Humans , Ornithine/antagonists & inhibitors , Ornithine/deficiency , Ornithine-Oxo-Acid Transaminase/metabolism , Polyamines/metabolism , gamma-Aminobutyric Acid/metabolism
7.
Biochem Pharmacol ; 42(5): 1045-52, 1991 Aug 08.
Article in English | MEDLINE | ID: mdl-1872891

ABSTRACT

Ornithine decarboxylase (ODC) activity of Ehrlich carcinoma cells was increased more than 36-fold after being maintained for 3.5 hr in vitro in a special chamber which allowed continuous perifusion with 0.5 mM ornithine; if incubated in vitro without perifusion the ODC activity was, of course, only 9-fold by the same concentration of ornithine. Ornithine withdrawal from the perifusion medium resulted in a decay of enzyme activity observed after 90 min; this decay was prevented by addition of 55 microM pyridoxal to the medium. The 1,4-diamines putrescine, spermidine, spermine, agmatine, histamine, serotonin, tryptamine, chlorpheniramine and harmaline at 55 microM strongly suppressed ODC induction by 0.5 mM ornithine in perifused Ehrlich ascites cells. Methyl derivatives also behave as strong inhibitors of ODC induction. On the contrary, N-acetylation paralleled with a decrease in the inhibition capacity: 55 microM N-acetyl putrescine, N-acetyl serotonin or N-omega-acetylhistamine suppressed ODC induction by ornithine in 66, 64 and 19%, respectively. The addition to the perifusion medium of the same concentrations of 1,3-diamines (1,3-diaminopropane, 1,3-diamino-2-propanol or the alkaloid gramine) as well as 1,5-diamines (1,5-diaminopentane and the antihistamic doxylamine or cimetidine) failed to suppress the induction of ODC activity by ornithine. Interestingly, 1,4-benzenediamine, which strongly inhibits ODC activity when the induced enzyme is assayed in its presence, did not suppress the induction of the enzyme when both 0.5 mM ornithine and 55 microM 1,4-benzenediamine were present in the perifusion medium. The inhibitory capacity in down-regulating ODC is not due to differences in the diamine uptake by the cells. The results suggest that the N-N distance (6A) and the charge of one amino group are important chemical characteristics for regulatory effects.


Subject(s)
Carcinoma, Ehrlich Tumor/enzymology , Ornithine Decarboxylase/metabolism , Ornithine/pharmacology , Polyamines/analysis , Alkaloids/pharmacology , Animals , Diamines/pharmacology , Enzyme Activation/drug effects , Harmaline/pharmacology , In Vitro Techniques , Indole Alkaloids , Ornithine/antagonists & inhibitors , Perfusion , Propanolamines/pharmacology
8.
Cancer Res ; 46(1): 47-53, 1986 Jan.
Article in English | MEDLINE | ID: mdl-3079590

ABSTRACT

We have studied the effects of partial polyamine depletion, induced by treatment with alpha-difluoromethylornithine (DFMO) on cell cycle phase distributions in five cultured human carcinoma cell lines. We used flow cytometry of cells stained with chromomycin-A3 and computer analysis to measure phase distributions of treated and control cultures. All five lines respond to 1-5 mM DFMO treatment with a total absence of measurable putrescine, a loss of greater than 90% of spermidine, and a 30-40% decline in spermine by 48 h after DFMO addition. The proliferation of all five lines is inhibited as well. Nonetheless, only four of the cell lines (HuTu-80, HT-29, MCF-7, and A-427) show a marked increase in the G1-phase fraction and decrease in the S-phase fraction as a consequence of DFMO treatment. Small, but significant, decreases in the G2-M populations of these cell lines also occurred after DFMO treatment. Exogenous putrescine (5-50 microM) reversed both the polyamine depletion and the perturbed phase distributions of DFMO-treated cultures but was without effect on phase distributions of cultures not treated with DFMO. The fifth cell line (ME-180) showed no effect of polyamine depletion on cell cycle phase distributions in DFMO-treated cultures and also no effect of exogenous putrescine on phase fractions of either control or DFMO-treated cells. These observations indicate that some human tumor cell lines are dependent upon adequate intracellular polyamine content for maintenance of cell cycle traverse. They also imply that human tumor cell lines are heterogeneous with regard to their cell cycle response to DFMO-induced polyamine deficiency.


Subject(s)
Cell Cycle/drug effects , Ornithine/analogs & derivatives , Polyamines/metabolism , Cell Line , DNA/analysis , Dose-Response Relationship, Drug , Eflornithine , Flow Cytometry , Humans , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Putrescine/pharmacology
9.
Biochem Pharmacol ; 35(2): 159-65, 1986 Jan 15.
Article in English | MEDLINE | ID: mdl-3080004

ABSTRACT

(E)-2-(fluoromethyl)dehydroornithine, a new enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) is no more effective than alpha-difluoromethylornithine (DFMO) at inhibiting polyamine biosynthesis in rat hepatoma tissue culture (HTC) cells and in rat organs even though its potency is over 15 times higher than that of DFMO in vitro. The methyl, ethyl, octyl and benzyl esters of (E)-2-(fluoromethyl)dehydroornithine were synthesized as potential prodrugs of the amino acid. When tested at concentration equivalent to the Ki value of the amino acid, they are devoid of ODC-inhibitory property. When measured 6 hr after its addition to the HTC cell culture medium, the absorption of methyl ester was 20 times higher than that of the parent amino acid or that of DFMO, and was accompanied by a more marked intracellular accumulation of (E)-2-(fluoromethyl)dehydroornithine than that achieved by the addition of the parent amino acid. The methyl ester used at 10 times lower concentrations is as effective as its parent amino acid or as DFMO at inhibiting polyamine biosynthesis in HTC cells. Similarly, the methyl and the ethyl esters of (E)-2-(fluoromethyl)dehydroornithine used at 10 times lower doses are as effective as the parent amino acid and as DFMO at inhibiting ODC in the ventral prostate of rat, 6 hr after oral administration. All the esters of (E)-2-(fluoromethyl)dehydroornithine produce a particularly long duration of ODC inhibition in the ventral prostate and in the testes. Repeated administration (25 mg/kg given once a day by gavage) of the methyl ester of (E)-2-(fluoromethyl)dehydroornithine for 8 days to rats results in a constant 80% inhibition of ODC over a 24-hr period, accompanied by a 90% decrease of putrescine and spermidine concentrations in the ventral prostate.


Subject(s)
Adenosylmethionine Decarboxylase/antagonists & inhibitors , Carboxy-Lyases/antagonists & inhibitors , Ornithine Decarboxylase Inhibitors , Ornithine/analogs & derivatives , Ornithine/antagonists & inhibitors , Animals , Cells, Cultured , Dose-Response Relationship, Drug , Eflornithine , Male , Ornithine/metabolism , Ornithine/pharmacology , Polyamines/metabolism , Prostate/enzymology , Rats , Testis/enzymology , Thymus Gland/enzymology
10.
Farmakol Toksikol ; 48(5): 25-8, 1985.
Article in Russian | MEDLINE | ID: mdl-4076416

ABSTRACT

The content of free amino acids in rat brain changes uniformly (serine, taurine, GABA, alanine, valine, cystine, leucin, phenylalanine) as a result of injecting rats with cyanide (60 mg/kg) or cyanide in conjunction with ethanol (0.5 g/kg). In addition, in the latter case the level of cysteic acid and ornithine decreases 2-fold.


Subject(s)
Amino Acids/metabolism , Brain/metabolism , Cyanamide/administration & dosage , Cyanides/administration & dosage , Acetaldehyde/metabolism , Aldehyde Dehydrogenase/antagonists & inhibitors , Aldehyde Dehydrogenase/metabolism , Animals , Cysteic Acid/antagonists & inhibitors , Drug Synergism , Ethanol/administration & dosage , Injections, Intraperitoneal , Male , Ornithine/antagonists & inhibitors , Rats
11.
Regul Pept ; 11(3): 201-8, 1985 Jul.
Article in English | MEDLINE | ID: mdl-3933061

ABSTRACT

The role of ornithine decarboxylase and of polyamines was investigated on caerulein-induced pancreatic growth through the use of alpha-difluoromethylornithine (DFMO) and putrescine. Caerulein, the cholecystokinin analog, given at a dose of 1 microgram . kg-1 three times a day was associated with pancreatic hyperplasia and hypertrophy after 2 and 4 days of treatment. The present study shows that putrescine, given once daily i.p. at a dose of 300 mumol . kg-1, can reverse the previously observed DFMO inhibition on pancreatic DNA content increments stimulated by caerulein. It was also observed that putrescine inhibits severely the 2-day caerulein-induced pancreatic hypertrophy, yet interferes only moderately with 4 days of caerulein treatment. These data lend further support to the involvement of ornithine decarboxylase and polyamines in induced pancreatic growth.


Subject(s)
Ceruletide/pharmacology , Ornithine Decarboxylase Inhibitors , Ornithine/analogs & derivatives , Pancreas/anatomy & histology , Putrescine/pharmacology , Animals , Body Weight/drug effects , DNA/isolation & purification , DNA Replication/drug effects , Eflornithine , Male , Organ Size/drug effects , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Pancreas/drug effects , Pancreas/metabolism , Rats , Rats, Inbred Strains
12.
Am J Vet Res ; 43(9): 1651-3, 1982 Sep.
Article in English | MEDLINE | ID: mdl-6816107

ABSTRACT

alpha-Difluoromethylornithine (DFMO; RMI 71,782) given in drinking water in concentrations as low as 0.0625% inhibited infections of Eimeria tenella and minimized the development of lesions in chickens. It had approximately the same activity as a currently used anticoccidial drug, amprolium, and also had the advantage of being relatively nontoxic in chickens. Body weight gains were not reduced in chickens given 0.0635% DFMO or less for 14 days starting 8 days before they were inoculated with oocysts, but were reduced in chickens given drinking water containing 0.125 and 0.25% DFMO. The anticoccidial activity of DFMO was completely reversed by injection (intraabdominal) of putrescine hydrochloride (300 mg/kg of body weight/day), indicating that the drug may act by blocking putrescine biosynthesis. Inoculated chickens, in which coccidial lesion development was suppressed by DFMO, resisted subsequent challenge exposure with E tenella, as did nontreated infected control birds which had recovered from infection.


Subject(s)
Chickens/parasitology , Coccidiosis/veterinary , Coccidiostats/therapeutic use , Ornithine/analogs & derivatives , Poultry Diseases/prevention & control , Animals , Cecal Diseases/prevention & control , Cecal Diseases/veterinary , Coccidiosis/prevention & control , Coccidiostats/antagonists & inhibitors , Eflornithine , Eimeria/drug effects , Male , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Ornithine/therapeutic use , Putrescine/pharmacology
14.
Biochim Biophys Acta ; 696(2): 179-86, 1982 Feb 26.
Article in English | MEDLINE | ID: mdl-6800405

ABSTRACT

The possibility that alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase could be used to prevent the rise in hepatic putrescine and spermidine content following partial hepatectomy was tested. Administration of alpha-difluoromethylornithine at a dose of 400 mg/kg every 4 h reduced hepatic putrescine to less than 2 nmol/g, but had only a small effect on the rise in spermidine seen at 28 h after partial hepatectomy. Such treatment also reduced the rise in DNA synthesis produced by partial hepatectomy by up to 70%. The inhibitory effect towards DNA synthesis could be reversed by administration of putrescine which increased the hepatic putrescine content to about 30-40% of that in the regenerating control livers. these results suggest that accumulation of putrescine rather than spermidine is needed for DNA synthesis after partial hepatectomy. They also suggest that part, but not all of the rise in putrescine normally seen in the liver after partial hepatectomy is needed for the enhanced DNA synthesis associated with liver regeneration. Experiments with lower doses of alpha-difluoromethylornithine showed that a substantial part of the rise in hepatic ornithine decarboxylase activity could be abolished without affecting either the rise in spermidine content or the increase in DNA synthesis after partial hepatectomy.


Subject(s)
DNA/biosynthesis , Liver Regeneration , Liver/metabolism , Polyamines/biosynthesis , Putrescine/pharmacology , Animals , Eflornithine , Male , Ornithine/analogs & derivatives , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Rats
15.
Med Biol ; 59(5-6): 347-53, 1981 Dec.
Article in English | MEDLINE | ID: mdl-6803078

ABSTRACT

The acetyl derivatives of polyamines, N1-acetylspermine (N1-AcSPM) and N1-acetylspermidine (N1-AcSPD), are in vitro better substrates of tissue polyamine oxidase than the corresponding non-acetylated polyamines. Rat hepatoma tissue culture (HTC) cells, depleted of their putrescine (PUT) and spermidine (SPD) content by the use of DL-alpha-difluoromethylornithine (DFMeOrn), an irreversible inhibitor of L-ornithine decarboxylase, were used to study in situ the catabolism of these acetyl derivatives of polyamines. Normal intracellular spermidine content was restored by the addition of N1-acetylspermidine to polyamine-deficient cells. Addition of spermine (SPM) did not restore the spermidine content, although this polyamine elevated the spermine content of the cells. N1-Acetylspermidine reestablished normal spermidine levels of the cells and elevated the cellular putrescine content more efficiently and more rapidly than spermidine. Monoacetylputrescine and N1, N12-diacetylspermine (di-AcSPM) were ineffective in restoring putrescine and spermidine contents. These findings support the concept that N1-acetylspermine and N1-acetylspermidine are natural substrates of tissue polyamine oxidase and suggest poor membrane permeability of monoacetylputrescine (AcPUT) and N1, N12-diacetylspermine. Furthermore, they indicate that acetylation of polyamines by the cytosolic acetyl CoA: polyamine N1-acetyltransferase is the rate-limiting step of polyamine catabolism in rat hepatoma cells. Growth inhibition by DL-alpha-difluoromethylornithine was reversed by N1-acetylspermine and N1-acetylspermidine but not by monoacetylputrescine and N1, N12-diacetylspermine. These results suggest again that the antiproliferative effect of DL-alpha-dilfuoromethylornithine is related to inhibition of polyamine biosynthesis.


Subject(s)
Liver Neoplasms, Experimental/enzymology , Polyamines/metabolism , Acetylation , Acetyltransferases/metabolism , Animals , Cell Division/drug effects , Cell Line , Eflornithine , Ornithine/analogs & derivatives , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Ornithine Decarboxylase Inhibitors , Oxidoreductases Acting on CH-NH Group Donors/metabolism , Polyamines/pharmacology , Rats , Polyamine Oxidase
17.
Proc Natl Acad Sci U S A ; 78(4): 2355-8, 1981 Apr.
Article in English | MEDLINE | ID: mdl-6264474

ABSTRACT

Many human small-cell lung carcinoma culture lines grow as multicellular aggregate spheroids, for which high L-dopa decarboxylase activity is a marker. During the initial cell aggregation and the exponential growth phase, there is a marked increase in ornithine decarboxylase activity and an accumulation of polyamines. alpha-Difluoromethylornithine, a specific enzyme-activated, irreversible ornithine decarboxylase inhibitor, blocks the increase in ornithine decarboxylase activity and in polyamines and inhibits human small-cell lung carcinoma cell growth. After the onset of a decreased proliferation rate, the multicellular spheroid aggregates become poorly formed, cell loss ensues, and there is a decrease in L-dopa decarboxylase activity. These findings support the hypothesis that ornithine decarboxylase and the polyamines play an essential role not only in the proliferative phase but also in the viability of human small-cell lung carcinoma cells in culture. The results suggest that alpha-difluoromethylornithine, a virtually nontoxic compound, may be potentially useful in the therapy of this human tumor.


Subject(s)
Carcinoma, Small Cell/pathology , Lung Neoplasms/pathology , Ornithine/analogs & derivatives , Polyamines/physiology , Cell Aggregation/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Cells, Cultured , Eflornithine , Humans , Ornithine/antagonists & inhibitors , Ornithine/pharmacology , Putrescine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...